Occudo Quantitative Strategies’s Black Diamond Therapeutics BDTX Stock Holding History

Occudo Quantitative Strategies’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,032	Closed	-$55.9K	–	757
2024 Q1	$55.9K	Sell	11,032 -7,102	-39%	-$28.6K	0.01%	687
2023 Q4	$51K	Sell	18,134 -8,628	-32%	-$20.2K	0.01%	736
2023 Q3	$76.8K	Buy	+26,762	New	+$98.6K	0.01%	895
2022 Q4	–	Sell	-18,764	Closed	-$32K	–	975
2022 Q3	$32K	Sell	18,764 -1,043	-5%	-$3.22K	﹤0.01%	1116
2022 Q2	$49K	Sell	19,807 -7,316	-27%	-$17K	﹤0.01%	1072
2022 Q1	$75K	Sell	27,123 -19,303	-42%	-$70.5K	0.01%	1046
2021 Q4	$247K	Buy	46,426 +7,144	+18%	+$49.9K	0.02%	831
2021 Q3	$332K	Sell	39,282 -66,114	-63%	-$653K	0.04%	694
2021 Q2	$1.28M	Buy	+105,396	New	+$2.08M	0.2%	145
2021 Q1	–	Sell	-10,466	Closed	-$335K	–	756
2020 Q4	$335K	Buy	+10,466	New	+$344K	0.11%	373

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Occudo Quantitative Strategies's BDTX Position: Q2 2024 in Review

Occudo Quantitative Strategies sold out of Black Diamond Therapeutics (BDTX) in Q2 2024, closing a stake of 11,032 shares — an estimated $55.9K sold.

Occudo Quantitative Strategies first reported a position in BDTX in Q4 2020 and held it in 10 quarters. The position peaked at $1.28M in Q2 2021. 90 funds tracked by Wall St. Rank hold BDTX as of Q2 2024.

Occudo Quantitative Strategies reported no remaining Black Diamond Therapeutics position as of Q2 2024 after selling out during the quarter.
Occudo Quantitative Strategies sold 11,032 Black Diamond Therapeutics shares in Q2 2024, an estimated $55.9K.
Occudo Quantitative Strategies first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 10 quarters.
Occudo Quantitative Strategies's Black Diamond Therapeutics position peaked at $1.28M in Q2 2021.
90 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.